IMMP - プリマ・バイオメッド (Immutep Limited) プリマ・バイオメッド

 IMMPのチャート


 IMMPの企業情報

symbol IMMP
会社名 Immutep Ltd (プリマ・バイオメッド)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種    医療関連(Health Care)
概要 事業概要 --   プリマ・バイオメッドはオ―ストラリアのバイオ医薬品会社。がん治療用の免疫療法医薬品の開発に従事する。主要パイプラインは、T細胞免疫反応の調節に重要な役割を果たすLAG-3の免疫制御システムを基にする。臨床段階の医薬品の一つは、T細胞免疫刺激因子(APC活性化因子)の「IMP321」、卵巣がん治療用の「CVac」である。本社はシドニ―。   
本社所在地 Level 12 95 Pitt Street Sydney New South Wales 2000 AUS
代表者氏名
代表者役職名
電話番号
設立年月日 31898
市場名 NASDAQ National Market System
ipoyear ―年
従業員数 17人
url www.primabiomed.com.au
nasdaq_url https://www.nasdaq.com/symbol/immp
adr_tso 7379595
EBITDA EBITDA ー
終値(lastsale) 3.2
時価総額(marketcap) 23614704
時価総額 時価総額 ―
売上高 売上高 --
企業価値(EV) 企業価値(EV) ー
当期純利益 当期純利益 --
決算概要 決算概要 --

 IMMPのテクニカル分析


 IMMPのニュース

   Biotech Immunotherapy Company Immutep Sets the Standard with its LAG-3 Research  2021/04/06 14:33:17 Benzinga
Immutep was one of the Benzinga Global Small Cap Conference sponsors on December 8-9, 2020. The information contained in this article in no way represents investment advice or opinion on the part of Benzinga or its writers and is intended for informational purposes only. Immutep Limited (ASX: IMM) (NASDAQ: IMMP ) is an innovative biotechnology company that develops novel immunotherapy treatments for cancer, infectious disease and autoimmune disease. The company is setting the global standard for the development of therapeutics that modulate Lymphocyte Activation Gene-3 or LAG-3, a cell surface molecule that plays a vital role in regulating T cells. The LAG-3 protein controls the signaling between specific immune cells, T cells and antigen-presenting cells (APCs), which are responsible for the adaptive immune response. Immutep not only leads the way with its LAG-3 research but sets the research standard because it was discovered by its Chief Scientific Officer and Chief Medical Officer Dr.
   60 Stocks Moving In Thursday's Mid-Day Session  2020/12/10 12:03:00 Benzinga
Gainers Immutep Limited (NASDAQ: IMMP) shares jumped 198.6% to $6.42 after the company said its Chinese partner, EOC Pharma will commence a new Phase 2 …
   42 Stocks Moving in Thursday's Pre-Market Session  2020/12/10 12:00:16 Benzinga
Gainers Immutep Limited (NASDAQ: IMMP ) rose 99.5% to $4.29 in … Full story available on Benzinga.com
   Immutep Limited (ASX:IMM) completes $29.6m placement to expand clinical development  2020/11/19 00:26:54 Finance News Network
19 Nov 2020 - Immutep Limited (ASX:IMM) is advancing clinical development for its lead product candidate eftilagimod alpha through the expansion of its ongoing TACTI-002 study and a new Phase II trial.
   IMMUTEP LTD/S (NASDAQ:IMMP) Stock Price Up 12.8%  2020/10/21 17:37:15 US Banking News
IMMUTEP LTD/S (NASDAQ:IMMP)’s stock price rose 12.8% during mid-day trading on Wednesday . The stock traded as high as $1.85 and last traded at $1.85. Approximately 283,513 shares were traded during trading, a decline of 62% from the average daily volume of 741,707 shares. The stock had previously closed at $1.64. Separately, Alliance Global Partners […]
   Biotech Immunotherapy Company Immutep Sets the Standard with its LAG-3 Research  2021/04/06 14:33:17 Benzinga
Immutep was one of the Benzinga Global Small Cap Conference sponsors on December 8-9, 2020. The information contained in this article in no way represents investment advice or opinion on the part of Benzinga or its writers and is intended for informational purposes only. Immutep Limited (ASX: IMM) (NASDAQ: IMMP ) is an innovative biotechnology company that develops novel immunotherapy treatments for cancer, infectious disease and autoimmune disease. The company is setting the global standard for the development of therapeutics that modulate Lymphocyte Activation Gene-3 or LAG-3, a cell surface molecule that plays a vital role in regulating T cells. The LAG-3 protein controls the signaling between specific immune cells, T cells and antigen-presenting cells (APCs), which are responsible for the adaptive immune response. Immutep not only leads the way with its LAG-3 research but sets the research standard because it was discovered by its Chief Scientific Officer and Chief Medical Officer Dr.
   60 Stocks Moving In Thursday's Mid-Day Session  2020/12/10 12:03:00 Benzinga
Gainers Immutep Limited (NASDAQ: IMMP) shares jumped 198.6% to $6.42 after the company said its Chinese partner, EOC Pharma will commence a new Phase 2 …
   42 Stocks Moving in Thursday's Pre-Market Session  2020/12/10 12:00:16 Benzinga
Gainers Immutep Limited (NASDAQ: IMMP ) rose 99.5% to $4.29 in … Full story available on Benzinga.com
   Immutep Limited (ASX:IMM) completes $29.6m placement to expand clinical development  2020/11/19 00:26:54 Finance News Network
19 Nov 2020 - Immutep Limited (ASX:IMM) is advancing clinical development for its lead product candidate eftilagimod alpha through the expansion of its ongoing TACTI-002 study and a new Phase II trial.
   IMMUTEP LTD/S (NASDAQ:IMMP) Stock Price Up 12.8%  2020/10/21 17:37:15 US Banking News
IMMUTEP LTD/S (NASDAQ:IMMP)’s stock price rose 12.8% during mid-day trading on Wednesday . The stock traded as high as $1.85 and last traded at $1.85. Approximately 283,513 shares were traded during trading, a decline of 62% from the average daily volume of 741,707 shares. The stock had previously closed at $1.64. Separately, Alliance Global Partners […]
   Biotech Immunotherapy Company Immutep Sets the Standard with its LAG-3 Research  2021/04/06 14:33:17 Benzinga
Immutep was one of the Benzinga Global Small Cap Conference sponsors on December 8-9, 2020. The information contained in this article in no way represents investment advice or opinion on the part of Benzinga or its writers and is intended for informational purposes only. Immutep Limited (ASX: IMM) (NASDAQ: IMMP ) is an innovative biotechnology company that develops novel immunotherapy treatments for cancer, infectious disease and autoimmune disease. The company is setting the global standard for the development of therapeutics that modulate Lymphocyte Activation Gene-3 or LAG-3, a cell surface molecule that plays a vital role in regulating T cells. The LAG-3 protein controls the signaling between specific immune cells, T cells and antigen-presenting cells (APCs), which are responsible for the adaptive immune response. Immutep not only leads the way with its LAG-3 research but sets the research standard because it was discovered by its Chief Scientific Officer and Chief Medical Officer Dr.
   60 Stocks Moving In Thursday's Mid-Day Session  2020/12/10 12:03:00 Benzinga
Gainers Immutep Limited (NASDAQ: IMMP) shares jumped 198.6% to $6.42 after the company said its Chinese partner, EOC Pharma will commence a new Phase 2 …
   42 Stocks Moving in Thursday's Pre-Market Session  2020/12/10 12:00:16 Benzinga
Gainers Immutep Limited (NASDAQ: IMMP ) rose 99.5% to $4.29 in … Full story available on Benzinga.com
   Immutep Limited (ASX:IMM) completes $29.6m placement to expand clinical development  2020/11/19 00:26:54 Finance News Network
19 Nov 2020 - Immutep Limited (ASX:IMM) is advancing clinical development for its lead product candidate eftilagimod alpha through the expansion of its ongoing TACTI-002 study and a new Phase II trial.
   IMMUTEP LTD/S (NASDAQ:IMMP) Stock Price Up 12.8%  2020/10/21 17:37:15 US Banking News
IMMUTEP LTD/S (NASDAQ:IMMP)’s stock price rose 12.8% during mid-day trading on Wednesday . The stock traded as high as $1.85 and last traded at $1.85. Approximately 283,513 shares were traded during trading, a decline of 62% from the average daily volume of 741,707 shares. The stock had previously closed at $1.64. Separately, Alliance Global Partners […]

 関連キーワード  (― 米国株 プリマ・バイオメッド IMMP Immutep Limited)

 twitter  (公式ツイッターやCEOツイッターなど)